Min­er­va suf­fers an­oth­er CNS de­feat; Eli Lil­ly wins OK for tau-based Alzheimer's di­ag­nos­tic

→ Months af­ter a de­press­ing end to Min­er­va Neu­ro­sciences‘ quest to de­vel­op a de­pres­sion drug, the Waltham, Mass­a­chu­setts-based drug de­vel­op­er un­veiled more bad news as its lead ex­per­i­men­tal com­pound — rolu­peri­done — failed to suc­ceed in a late-stage schiz­o­phre­nia study. The Achilles heel of many a CNS fail­ure reared its ug­ly head again: the dread­ed larg­er-than-life place­bo ef­fect. But com­pa­ny chief Rémy Luthringer isn’t throw­ing in the tow­el just yet.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER